Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Milnacipran HCl Tablets Articles

Forest Labs buys Bystolic rights from Janssen for $357 million

3 April 2012

Pierre Fabre gains approval for fibromyalgia drug Joncia in Australia; TGA cancels approval for four painkillers

22 November 2011

Cypress Bioscience finally succumbs to Ramius advances, but at $6.50/share in cash

16 December 2010

US consumer group calls for withdrawal Forest/Cypress fibromyalgia drug Savella

22 January 2010

US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results

21 October 2009

Cypress and Forest Labs' Savella to go on sales in the USA on April 28

23 April 2009

Cypress a top small biotech pick, says Zacks

23 March 2009

Stock Commentary - New York week to Mar 9, 2009

16 March 2009

Forest/Cypress' fibromyalgia drug cleared in USA

26 January 2009

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Daiichi Sankyo files for Japanese approval of Prasugrel

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS